FDA approves Keytruda in cervical cancer, PMBCL

Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE